Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study

D Gareth Evans,1* Susan Astley,2 Paula Stavrinos,3 Elaine Harkness,2 Louise S Donnelly,3 Sarah Dawe,3 Ian Jacob,4 Michelle Harvie,3 Jack Cuzick,5 Adam Brentnall,5 Mary Wilson,3 Fiona Harrison,6 Katherine Payne4 and Anthony Howell2,3

1Department of Genomic Medicine, Institute of Human Development, Manchester Academic Health Science Centre (MAHSC), Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
2Institute of Population Health, Centre for Imaging Sciences, University of Manchester, Manchester, UK
3The Nightingale Centre and Genesis Prevention Centre, University Hospital of South Manchester, Manchester, UK
4Department of Health Economics, University of Manchester, Manchester, UK
5Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
6Patient representative

*Corresponding author

Declared competing interests of authors: Jack Cuzick reports grants from AstraZeneca for being on the advisory board, and funding of the prevention trial outside the submitted work.

Published August 2016
DOI: 10.3310/pgfar04110

Plain English summary

Risk prediction, early detection and prevention of breast cancer

Programme Grants for Applied Research 2016; Vol. 4: No. 11
DOI: 10.3310/pgfar04110

NIHR Journals Library www.journalslibrary.nihr.ac.uk
In the UK, women are invited for 3-yearly breast screening through the NHS Breast Screening Programme (NHSBSP) from the ages of 47–50 years to the ages of 69–73 years. Women who have family histories of breast cancer can obtain enhanced screening from the age of 40 years. Risk prediction models are able, using known risk factors such as family history/hormonal/reproductive factors, to categorise women by risk, although accurate individual risk prediction has remained difficult. The identification of other important risk factors such as mammographic breast density (MD) and common variations in a person’s genes (single nucleotide polymorphisms) has made it possible to improve breast cancer risk prediction models. We have shown, in two large studies of over 63,000 women, that the Tyrer–Cuzick (TC) risk prediction model accurately predicts breast cancer risk, although further improvements are probably required.

Risk identification is improved by using deoxyribonucleic acid (DNA) and a visual assessment of MD. In the NHSBSP, using a combination of TC and MD predicts that 70% of the population with average or below average risks have very low rates of advanced breast cancer. A preliminary analysis suggested that using a risk-based screening programme could be a good use of NHS resources. However, more research is needed to generate evidence of the impact of introducing the proposed risk-based screening programme at a national level on health-care resource use and patient benefits.

We conclude that risk precision can be improved significantly by using DNA and MD, and can potentially be used to stratify NHSBSP screening to identify those at greater risk of high-stage cancers for enhanced screening, but that 3-yearly screening appears effective in 70% of the population.
Programme Grants for Applied Research

ISSN 2050-4322 (Print)
ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Programme Grants for Applied Research journal
Reports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme
The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report
The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0707-10031. The contractual start date was in January 2009. The final report began editorial review in September 2014 and was accepted for publication in October 2015. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Evans et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Programme Grants for Applied Research Editor-in-Chief

Professor Paul Little Professor of Primary Care Research, University of Southampton, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk